Metabolism Drugs Market, By Therapy Type (Enzyme Replacement Therapy, Substrate Reduction Therapy, Small Molecule Drugs, and Others), By Application (Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism Disease, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2029

Report Code: PMI5118 | Publish Date: March 2024 | No. of Pages: 176

Global Metabolism Drugs Market By Overview

Metabolism disorders are associated with impaired metabolism processes leading the body to have either too much or too little of essential substances needed to stay healthy. Metabolism disorders can be develop due to malfunctioning of certain organs such as pancreas or liver, deficiency of certain hormone or enzyme, consumption of too much of certain foods and also due to the genetic mutation. The most common metabolic disorders includes sickle cell anemia, cystic fibrosis, Gaucher’s disease, maple syrup urine disease, among others.

Rising prevalence of wide variety of metabolic disorders, worldwide is expected to support the growth of market. Key manufactures engaged in research and development activities in order to derive novel therapies such as enzyme replacement therapies and gaining drug approval in the treatment of metabolic disorders, will spur the growth of market. For instance, in August 2018, U.S. Food and Drug Administration (FDA) granted accelerated approval to Amicus Therapeutics’ Galafold (migalastat) 123 mg capsules in the treatment of adults with a confirmed diagnosis of Fabry disease. 

The metabolism drugs market has been segmented on the basis of therapy type, application, distribution channel and region.

On the basis of therapy type, the metabolism drugs market is segmented into enzyme replacement therapy, substrate reduction therapy, small molecule drugs and others.

Further, on the basis ofapplication, the metabolism drugs market is segmented into glycogen metabolism disease, lipid metabolism disease, amino acid metabolism disease, and others. 

Distribution channel for metabolism drugs market includes hospital pharmacies, retail pharmacies and online pharmacies. 

On the basis of region, the target market has been segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. 

The key players operating in the metabolism drugs market include Amicus Therapeutics Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, Merck & Co., Inc., Novartis AG, and Shire Plc.

Global Metabolism Drugs Market By Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
    • PORTER’s
    • Investment Outlook
  3. Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for Metabolism Drugs Strategies
      • Key Questions this Study will Answer
      • By Therapy Type (Enzyme Replacement Therapy, Substrate Reduction Therapy, Small Molecule Drugs, and Others)

        By Application (Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism Disease, and Others)

        By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) 

        By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Overview
    • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
    • Y-o-Y Growth Analysis (%), 2020 – 2030
    • Regional Trends
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Regional Analysis
    • Regional Revenue Analysis
    • Regional By segment Analysis
    • Reasons for regional growth
    • Key Player of particular region
    • Countries Include in the report:
      • North America (U.S., Canada)
      • Europe (UK, France, Germany, Russia, Italy, Rest of Europe)
      • Asia Pacific (India, Japan, South Korea, China, Rest of Asia Pacific)
      • Latin America (Brazil, Mexico, Rest of Latin America)
      • Middle East & Africa (GCC, Israel, South Africa, Rest of Middle East)
  1. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
    • Competitive Overview
    • Competitive Benchmarking
    • Market Share Analysis
    • Key Developments In The Global Metabolism Drugs Market
    • Key Developments: Mergers & Acquisitions
    • Key Developments: Collaboration
    • Key Developments: Contracts & Agreements
    • Key Developments: Expansion
    • Key Developments: Product Developments
  2. Company Profiles
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
  • SWOT Analysis
    • Amicus Therapeutics Inc.

    • AstraZeneca plc

    • Boehringer Ingelheim GmbH

    • Merck & Co., Inc., 

    • Novartis AG

    • Shire Plc.

  1. The Last Word
    • Future Impact
    • About Us
    • Contact

 

FAQs

The metabolism drugs market has been segmented on the basis of therapy type, application, distribution channel and region.

Rising prevalence of wide variety of metabolic disorders, worldwide is expected to support the growth of market.

North America is expected to account major market share as compared to that of other regions.

The key players operating in the metabolism drugs market include Amicus Therapeutics Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, Merck & Co., Inc., Novartis AG, and Shire Plc.

Treatment can affect the cells of the body and can cause serious disease such as cancer.